Base de dados : MEDLINE
Pesquisa : E01.370.225.625.625.100 [Categoria DeCS]
Referências encontradas : 2539 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 254 ir para página                         

  1 / 2539 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28817760
[Au] Autor:Hong SN; Yun HC; Yoo JH; Lee SH
[Ad] Endereço:Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Korea University Ansan Hospital, Ansan-si, Republic of Korea.
[Ti] Título:Association Between Hypercoagulability and Severe Obstructive Sleep Apnea.
[So] Source:JAMA Otolaryngol Head Neck Surg;143(10):996-1002, 2017 Oct 01.
[Is] ISSN:2168-619X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Obstructive sleep apnea (OSA) is related to the increased risk of cardiovascular disease. Although the pathogenesis of this association remains unclear, an alteration in coagulability is suspected as a link. Objective: To investigate the association between the severity of OSA and blood coagulability. Design, Setting, and Participants: A retrospective cohort study conducted at a tertiary care university hospital evaluated 146 patients with OSA from January 1, 2009, to July 31, 2015. The participants were divided into 4 groups according to the severity of OSA: control, mild, moderate, and severe. Main Outcomes and Measures: Association between the severity of OSA and coagulation test results, including platelet count, bleeding time, prothrombin time (PT) in seconds and as international normalized ratio (INR), and activated partial thromboplastin time. Results: Of the 146 patients, 135 (92.5%) were men; mean (SD) age was 34.8 (11.1) years. The control group included 41 (28.1%) patients; mild OSA, 32 (21.9%); moderate OSA, 30 (20.5%); and severe OSA, 43 (29.5%). Significant correlations were found between the apnea-hypopnea index and the PT seconds (Spearman r coefficient, -0.30; 95% CI, -0.44 to -0.14) and PT INR (Spearman r coefficient, -0.30; 95% CI, -0.44 to -0.14). There were significant differences between the OSA severity groups for PT seconds for the control group (mean, 11.26 [0.78] seconds) vs the moderate OSA group (10.74 [0.62] seconds; mean difference [MD], 0.52; 95% CI, 0.27 to 1.01) and the severe OSA group (10.67 [0.77] seconds; MD, 0.59; 95% CI, 0.14 to 1.03). Significant differences were also noted in PT INR between the control group (1.00 [0.07]) vs the moderate OSA group (0.95 [0.05]; MD, 0.04; 95% CI, 0.01 to 0.07) and the severe OSA group (0.94 [0.07]; MD, 0.05; 95% CI, 0.02 to 0.08). However, there was no significant difference between the control and mild OSA groups in PT seconds. Conclusions and Relevance: These results suggest that patients with moderate to severe OSA have elevated blood coagulability markers compared with healthy individuals, which may contribute to the occurrence of cardiovascular complications.
[Mh] Termos MeSH primário: Apneia Obstrutiva do Sono/sangue
Apneia Obstrutiva do Sono/complicações
Trombofilia/etiologia
[Mh] Termos MeSH secundário: Adulto
Tempo de Sangramento
Testes de Coagulação Sanguínea
Feminino
Seres Humanos
Masculino
Meia-Idade
Contagem de Plaquetas
Polissonografia
Estudos Retrospectivos
Fatores de Risco
Índice de Gravidade de Doença
Apneia Obstrutiva do Sono/fisiopatologia
Trombofilia/diagnóstico
Trombofilia/fisiopatologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170818
[St] Status:MEDLINE
[do] DOI:10.1001/jamaoto.2017.1367


  2 / 2539 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28598242
[Au] Autor:Zhang YL; Xi MZ; Choi YB; Lee BH
[Ad] Endereço:Department of Food and Nutrition, Chung-Ang University , Anseong-si, Gyeonggi-do, Korea.
[Ti] Título:Antithrombotic Effect of Fermented Ophiopogon japonicus in Thrombosis-Induced Rat Models.
[So] Source:J Med Food;20(7):637-645, 2017 Jul.
[Is] ISSN:1557-7600
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In this study, the antithrombotic and thrombolytic ability of second fermented extract of Ophiopogon japonicus (FEOJ) was verified in thrombosis-induced rats. Thrombosis was induced by oral administration of 2% carrageenan for 4 weeks. Five experimental groups (n = 9/group) involved in the study were control group, thrombosis group, low-dose FEOJ group (2 mL/kg, low-dose Ophiopogon japonicus [LOJ]), middle-dose FEOJ group (6 mL/kg, medium-dose Ophiopogon japonicus [MOJ]), and high-dose FEOJ group (12 mL/kg, high-dose Ophiopogon japonicus [HOJ]). The clotting time (CT), bleeding time (BT), prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen (FBG) were assessed in blood samples, and histological studies were performed on liver and lung tissues. The results demonstrated delayed CT only in MOJ and HOJ groups and delayed BT in all FEOJ groups compared with those in thrombosis and control groups (P < .05). Similarly, APTT was significantly delayed only in MOJ and HOJ groups, and PT was significantly delayed in all FEOJ groups, compared with those in control and thrombosis groups (P < .05). Although concentrations of FBG were similar in control, thrombosis, and LOJ groups, the tendency for decreased concentration of FBG (statistically nonsignificant) in MOJ and HOJ groups has been observed. Histological examination of livers and lungs revealed that thrombosis was partially improved in FEOJ group compared with the thrombosis group. In conclusion, CT, BT, PT, and APTT were prolonged in FEOJ group more than in control and thrombosis groups, thereby, depicting antithrombotic and thrombolytic effects. However, concentration-dependent effects of FEOJ were more prominent in MOJ and HOJ groups than in the LOJ group.
[Mh] Termos MeSH primário: Anticoagulantes/administração & dosagem
Ophiopogon/química
Extratos Vegetais/administração & dosagem
Trombose/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Anticoagulantes/isolamento & purificação
Anticoagulantes/metabolismo
Tempo de Sangramento
Coagulação Sanguínea/efeitos dos fármacos
Carragenina/efeitos adversos
Fermentação
Seres Humanos
Lactobacillaceae/metabolismo
Masculino
Ophiopogon/microbiologia
Extratos Vegetais/isolamento & purificação
Extratos Vegetais/metabolismo
Tempo de Protrombina
Ratos
Ratos Sprague-Dawley
Trombose/sangue
Trombose/induzido quimicamente
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Plant Extracts); 9000-07-1 (Carrageenan)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170825
[Lr] Data última revisão:
170825
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170610
[St] Status:MEDLINE
[do] DOI:10.1089/jmf.2016.3872


  3 / 2539 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28403362
[Au] Autor:Gocmen G; Aktop S; Tüzüner B; Goker B; Yarat A
[Ad] Endereço:Marmara University, Faculty of Dentistry, Department of Oral and Maxillofacial Surgery, Istanbul, Turkey.
[Ti] Título:Effects of hyaluronic acid on bleeding following third molar extraction.
[So] Source:J Appl Oral Sci;25(2):211-216, 2017 Mar-Apr.
[Is] ISSN:1678-7765
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Objective: To explore the effects of hyaluronic acid (HA) on bleeding and associated outcomes after third molar extraction. Methods: Forty patients who had undergone molar extraction were randomly divided into two groups; 0.8% (w/v) HA was applied to the HA group (n=20) whereas a control group (n=20) was not treated. Salivary and gingival tissue factor (TF) levels, bleeding time, maximum interincisal opening (MIO), pain scored on a visual analog scale (VAS), and the swelling extent were compared between the two groups. Results: HA did not significantly affect gingival TF levels. Salivary TF levels increased significantly 1 week after HA application but not in the control group. Neither the VAS pain level nor MIO differed significantly between the two groups. The swelling extent on day 3 and the bleeding time were greater in the HA group than in the control group. Conclusions: Local injection of HA at 0.8% prolonged the bleeding time, and increased hemorrhage and swelling in the early postoperative period after third molar extractions.
[Mh] Termos MeSH primário: Anti-Inflamatórios/efeitos adversos
Ácido Hialurônico/efeitos adversos
Dente Serotino/cirurgia
Hemorragia Pós-Operatória/induzido quimicamente
Extração Dentária/efeitos adversos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Tempo de Sangramento
Gengiva/química
Seres Humanos
Medição da Dor
Estudos Prospectivos
Valores de Referência
Saliva/química
Estatísticas não Paramétricas
Tromboplastina/análise
Fatores de Tempo
Extração Dentária/métodos
Resultado do Tratamento
Cicatrização/efeitos dos fármacos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 9004-61-9 (Hyaluronic Acid); 9035-58-9 (Thromboplastin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170530
[Lr] Data última revisão:
170530
[Sb] Subgrupo de revista:D; IM
[Da] Data de entrada para processamento:170414
[St] Status:MEDLINE


  4 / 2539 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28249709
[Au] Autor:Nakamura M; Takeuchi T; Kawahara T; Hirose J; Nakayama K; Hosaka Y; Furusako S
[Ad] Endereço:Discovery Research, Mochida Pharmaceutical Co., Ltd., 722 Jimba-aza-Uenohara, Gotemba, Shizuoka 412-8524, Japan. Electronic address: mnakamur@mochida.co.jp.
[Ti] Título:Simultaneous targeting of CD14 and factor XIa by a fusion protein consisting of an anti-CD14 antibody and the modified second domain of bikunin improves survival in rabbit sepsis models.
[So] Source:Eur J Pharmacol;802:60-68, 2017 May 05.
[Is] ISSN:1879-0712
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Severe sepsis is a complex, multifactorial, and rapidly progressing disease characterized by excessive inflammation and coagulation following bacterial infection. To simultaneously suppress pro-inflammatory and pro-coagulant responses, we genetically engineered a novel fusion protein (MR1007) consisting of an anti-CD14 antibody and the modified second domain of bikunin, and evaluated the potential of MR1007 as an anti-sepsis agent. Suppressive effects of MR1007 on lipopolysaccharide (LPS)-induced inflammatory responses were assessed using peripheral blood mononuclear cells or endothelial cells. Its inhibitory activity against the coagulation factor XIa was assessed using a purified enzyme and a chromogenic substrate. Anticoagulant activity was assessed using human or rabbit plasma. Anti-inflammatory and anti-coagulant effects and/or survival benefits were evaluated in an endotoxemia model and a cecal ligation and puncture model. MR1007 inhibited LPS-induced cytokine production in peripheral blood mononuclear cells and endothelial cells, inhibited factor XIa, and exhibited anticoagulant activity. In an endotoxemia model, 0.3-3mg/kg MR1007 suppressed pro-inflammatory and pro-coagulant responses in a dose-dependent manner; at a dose of 3mg/kg, the protein improved survival even when administered 8h after the LPS injection. In addition, 10mg/kg MR1007 administered 2h post cecal ligation and puncture improved survival. However, MR1007 administered at doses up to 30mg/kg did not increase ear bleeding time or bacterial counts in the cecal ligation and puncture model. Thus, simultaneous targeting of CD14 and factor XIa improves survival in the rabbit endotoxemia and sepsis models and represents a promising approach for the treatment of severe sepsis.
[Mh] Termos MeSH primário: alfa-Globulinas/química
Anticorpos Monoclonais/farmacologia
Endotoxemia/tratamento farmacológico
Fator XIa/antagonistas & inibidores
Receptores de Lipopolissacarídeos/imunologia
Terapia de Alvo Molecular
Proteínas Recombinantes de Fusão/farmacologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Monoclonais/imunologia
Anticorpos Monoclonais/uso terapêutico
Anticoagulantes/imunologia
Anticoagulantes/farmacologia
Anticoagulantes/uso terapêutico
Tempo de Sangramento
Modelos Animais de Doenças
Selectina E/metabolismo
Endotoxemia/metabolismo
Regulação da Expressão Gênica/efeitos dos fármacos
Seres Humanos
Interleucina-6/biossíntese
Domínios Proteicos
Coelhos
Proteínas Recombinantes de Fusão/imunologia
Proteínas Recombinantes de Fusão/uso terapêutico
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alpha-Globulins); 0 (Antibodies, Monoclonal); 0 (Anticoagulants); 0 (E-Selectin); 0 (Interleukin-6); 0 (Lipopolysaccharide Receptors); 0 (Recombinant Fusion Proteins); 0 (alpha-1-microglobulin); EC 3.4.21.27 (Factor XIa)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170303
[St] Status:MEDLINE


  5 / 2539 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27914964
[Au] Autor:Ktari N; Trabelsi I; Bardaa S; Triki M; Bkhairia I; Ben Slama-Ben Salem R; Nasri M; Ben Salah R
[Ad] Endereço:Laboratory of Enzyme Engineering and Microbiology, National School of Engineering of Sfax, University of Sfax, P.O. 1173-3038, Sfax, Tunisia.
[Ti] Título:Antioxidant and hemolytic activities, and effects in rat cutaneous wound healing of a novel polysaccharide from fenugreek (Trigonella foenum-graecum) seeds.
[So] Source:Int J Biol Macromol;95:625-634, 2017 Feb.
[Is] ISSN:1879-0003
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The aim of this work was to evaluate the antioxidant and hemolytic activities as well as the in vivo wound healing performance of a novel polysaccharide (FWEP) extracted from fenugreek (Trigonella foenum-graecum) seeds. The antioxidant activity was evaluated in vivo and in vitro using various assays. Results showed that FWEP exhibited strong antioxidant activities but no hemolytic activity was observed towards bovine erythrocytes. The application of FWEP hydrogel on the wound site in a rat model enhanced significantly wound healing activity and accelerated the wound closure after 14days of wound induction. Histological examination also demonstrated fully re-epithelialized wound with a complete epidermal regeneration. Altogether, these evidences demonstrated that FWEP had strong wound healing potential presumably achieved through its antioxidant activities.
[Mh] Termos MeSH primário: Antioxidantes/farmacologia
Hemólise/efeitos dos fármacos
Polissacarídeos/farmacologia
Sementes/química
Pele/efeitos dos fármacos
Trigonella/química
Cicatrização/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Antioxidantes/química
Biomarcadores/metabolismo
Compostos de Bifenilo/química
Tempo de Sangramento
Peso Corporal/efeitos dos fármacos
Peróxido de Hidrogênio/metabolismo
Hidroxiprolina/metabolismo
Ferro/química
Masculino
Oxirredução/efeitos dos fármacos
Estresse Oxidativo/efeitos dos fármacos
Picratos/química
Polissacarídeos/química
Ratos
Ratos Wistar
Pele/metabolismo
Fenômenos Fisiológicos da Pele/efeitos dos fármacos
beta Caroteno/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Biomarkers); 0 (Biphenyl Compounds); 0 (Picrates); 0 (Polysaccharides); 01YAE03M7J (beta Carotene); BBX060AN9V (Hydrogen Peroxide); DFD3H4VGDH (1,1-diphenyl-2-picrylhydrazyl); E1UOL152H7 (Iron); RMB44WO89X (Hydroxyproline)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170411
[Lr] Data última revisão:
170411
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161205
[St] Status:MEDLINE


  6 / 2539 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27560602
[Au] Autor:Chen Y; Yang W; Guo L; Wu X; Zhang T; Liu J; Zhang J
[Ad] Endereço:a Department of Cardiology , No. 9 People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine , Shanghai , China.
[Ti] Título:Atractylodes lactone compounds inhibit platelet activation.
[So] Source:Platelets;28(2):194-202, 2017 Mar.
[Is] ISSN:1369-1635
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Platelets play a crucial role in the development and progression of atherosclerosis-thrombosis and, therefore, antiplatelet drugs are widely used in the treatment of coronary artery disease. Moreover, advances in understanding the biological functions of natural plant products can provide new pharmacological strategies aimed at promoting cardiovascular health. Atractylenolide I (ATL-1), ATL-2, and ATL-3 are the major bioactive components of a Qi tonifying medicinal herb Rhizoma Atractylodis Macrocephalae (Atractylodes macrocephala), which is commonly used in traditional Chinese medicine (TCM). These components possess well-documented anti-inflammatory and anticancer activities, but their effects on platelet activation are still unknown. In this study, the effects of ATL on platelet function in vitro and in vivo were investigated, and the underlying mechanism was explored. We found that ATL-2 and ATL-3 but not ATL-1 diminished agonist-induced platelet aggregation and diminished adenosine triphosphate (ATP) release from dense granules. The levels of phospho-Akt (Ser473) and phospho-p38 MAPK were downregulated in the presence of ATL-2 and ATL-3. We also found that ATL-2 and ATL-3 have a similar inhibitory effect on platelet activation as acetylsalicylic acid in response to agonists. Furthermore, ATL-2 and ATL-3 diminished the spreading of human platelets on immobilized fibrinogen (Fg), delayed clot retraction in platelet-depleted plasma containing human platelets, extended first occlusion time in a mouse model of ferric chloride (FeCl )-induced carotid arterial thrombosis, and prolonged the bleeding time. These observations suggest that ATL-2 and ATL-3 are potential candidate therapeutic drugs for the prevention of thrombosis.
[Mh] Termos MeSH primário: Atractylodes/química
Plaquetas/efeitos dos fármacos
Lactonas/farmacologia
Extratos Vegetais/farmacologia
Ativação Plaquetária/efeitos dos fármacos
Inibidores da Agregação de Plaquetas/farmacologia
[Mh] Termos MeSH secundário: Trifosfato de Adenosina/secreção
Animais
Tempo de Sangramento
Plaquetas/metabolismo
Retração do Coágulo
GTP Fosfo-Hidrolases/metabolismo
GTP Fosfo-Hidrolases/farmacologia
Hemostasia/efeitos dos fármacos
Lactonas/química
Camundongos
Fosforilação
Extratos Vegetais/química
Agregação Plaquetária/efeitos dos fármacos
Inibidores da Agregação de Plaquetas/química
Proteínas Proto-Oncogênicas c-akt/metabolismo
Trombose/sangue
Trombose/tratamento farmacológico
Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Lactones); 0 (Plant Extracts); 0 (Platelet Aggregation Inhibitors); 8L70Q75FXE (Adenosine Triphosphate); EC 2.7.11.1 (Proto-Oncogene Proteins c-akt); EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases); EC 3.6.1.- (GTP Phosphohydrolases)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170406
[Lr] Data última revisão:
170406
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160826
[St] Status:MEDLINE
[do] DOI:10.1080/09537104.2016.1209477


  7 / 2539 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27481874
[Au] Autor:Frank RD; Lanzmich R; Haager PK; Budde U
[Ad] Endereço:1 Department of Nephrology and Clinical Immunology, University Hospital, RWTH Aachen, Eschweiler, Germany.
[Ti] Título:Severe Aortic Valve Stenosis.
[So] Source:Clin Appl Thromb Hemost;23(3):229-234, 2017 Apr.
[Is] ISSN:1938-2723
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Aortic valve stenosis (AVS) is the most common valve disease in adults. Severe forms are associated with acquired von Willebrand syndrome (aVWS) with loss of the largest von Willebrand factor (VWF) multimers. Diagnostic gold standard is the VWF multimer analysis. Valve replacement rapidly restores the VWF structure. Uncertainty exists if this effect is permanent and how functional VWF assays perform compared with multimer analysis. We studied 21 consecutive patients with severe AVS before and 6 to 18 months after valve surgery and compared them with 14 controls without valve disease referred for coronary angiography. The VWF multimers, VWF antigen (VWF:Ag), VWF collagen binding capacity (VWF:CB), VWF:CB/VWF:Ag ratio, in vitro bleeding time (PFA-100), factor VIII coagulation activity (FVIII:C), and VWF ristocetin cofactor activity (VWF:RCo) were determined. In all patients with AVS, the large VWF multimers were strongly reduced (56 ± 13% of normal plasma); all controls had normal multimers. The PFA-100 collagen/ADP closure times (coll/ADP CT) were prolonged in patients with AVS compared with the controls (175 ± 56 seconds vs 86 ± 14 seconds, P < .001). The VWF:CB/VWF:Ag ratio was pathological in 20 of the 21 patients but normal in controls. After surgery, the multimers normalized in all patients and coll/ADP CT shortened (pre 184 ± 65 seconds vs post 102 ± 22 seconds; P < .001). The VWF:CB/VWF:Ag ratio strongly improved ( P < .001) and normalized in 14 of 17 patients. In conclusion, all consecutive patients with severe AVS had an aVWS. The combination of coll/ADP CT and VWF:CB/VWF:Ag ratio detected the aVWS in all patients. More than 6 months after valve replacement, the VWF multimers were still normalized in all patients indicating a permanent cure of the aVWS.
[Mh] Termos MeSH primário: Estenose da Valva Aórtica/cirurgia
Doenças de von Willebrand/cirurgia
Fator de von Willebrand/metabolismo
[Mh] Termos MeSH secundário: Estenose da Valva Aórtica/complicações
Tempo de Sangramento
Testes de Coagulação Sanguínea
Estudos de Casos e Controles
Implante de Prótese de Valva Cardíaca
Seres Humanos
Multimerização Proteica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (von Willebrand Factor)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170309
[Lr] Data última revisão:
170309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160803
[St] Status:MEDLINE
[do] DOI:10.1177/1076029616660759


  8 / 2539 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27981920
[Au] Autor:Chaudhary HT
[Ad] Endereço:Department of Pathology, Medical College, Taif University, Taif, Saudi Arabia.
[Ti] Título:In-Silico Analysis of Amotosalen Hydrochloride Binding to CD-61 of Platelets.
[So] Source:J Coll Physicians Surg Pak;26(11):881-886, 2016 Nov.
[Is] ISSN:1681-7168
[Cp] País de publicação:Pakistan
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To determine the docking of Amotosalen hydrochloride (AH) at CD-61 of platelets, and to suggest the cause of bleeding in AH treated platelets transfusion. STUDY DESIGN: Descriptive study. PLACE AND DURATION OF STUDY: Medical College, Taif University, Taif, Saudi Arabia, from October 2014 to May 2015. METHODOLOGY: The study was carried out in-silico. PDB (protein data bank) code of Tirofiban bound to CD-61 was 2vdm. CD-61 was docked with Tirofiban using online docking tools, i.e. Patchdock and Firedock. Then, Amotosalen hydrochloride and CD-61 were also docked. Best docking poses to active sites of 2vdm were found. Ligplot of interactions of ligands and CD-61 were obtained. Then comparison of hydrogen bonds, hydrogen bond lengths, and hydrophobic bonds of 2vdm molecule and best poses of docking results were done. Patchdock and Firedock results of best poses were also analysed using SPSS version 16. RESULTS: More amino acids were involved in hydrogen and hydrophobic bonds in Patchdock and Firedock docking of Amotosalen hydrochloride with CD-61 than Patchdock and Firedock docking of CD-61 with Tirofiban. The binding energy was more in latter than former. CONCLUSION: Amotosalen hydrochloride binds to the active site of CD-61 with weaker binding force. Haemorrhage seen in Amotosalen hydrochloride-treated platelets might be due to binding of Amotosalen hydrochloride to CD-61.
[Mh] Termos MeSH primário: Plaquetas/efeitos dos fármacos
Simulação por Computador
Furocumarinas/farmacologia
Fármacos Fotossensibilizantes/farmacologia
Inibidores da Agregação de Plaquetas/farmacologia
Tirosina/análogos & derivados
[Mh] Termos MeSH secundário: Tempo de Sangramento
Hemorragia/etiologia
Hemorragia/prevenção & controle
Seres Humanos
Tirosina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Furocoumarins); 0 (Photosensitizing Agents); 0 (Platelet Aggregation Inhibitors); 42HK56048U (Tyrosine); GGX234SI5H (tirofiban); K1LDZ0VBC0 (amotosalen)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170502
[Lr] Data última revisão:
170502
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161217
[St] Status:MEDLINE


  9 / 2539 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27965976
[Au] Autor:Xiang Q; Ji SD; Zhang Z; Zhao X; Cui YM
[Ad] Endereço:Department of Pharmacy, Base for Clinical Trial, Peking University First Hospital, Beijing 100034, China.
[Ti] Título:Identification of and Single-Nucleotide Polymorphisms and Their Influences on the Platelet Function.
[So] Source:Biomed Res Int;2016:5675084, 2016.
[Is] ISSN:2314-6141
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The aim of the study was to investigate and genetic polymorphisms and to evaluate the variability in the platelet function in healthy Chinese subjects. The genetic sequence of the entire coding region of the and genes was investigated. Adenosine diphosphate-induced platelet aggregation, glycoprotein IIb/IIIa content, bleeding time, and coagulation indexes were detected. Thirteen variants in the locus and 29 variants in the locus were identified in the Chinese population. The rs1009312 and rs2015049 were associated with the mean platelet volume. The rs70940817 was significantly correlated with the prothrombin time. The rs70940817 and rs112188890 were related with the activated partial thromboplastin time, and rs4642 was correlated with the thrombin time and fibrinogen. The minor alleles of rs56197296 and rs5919 were associated with decreased ADP-induced platelet aggregation, and rs55827077 was related with decreased GPIIb/IIIa per platelet. The rs1009312, rs2015049, rs3760364, rs567581451, rs7208170, and rs117052258 were related with bleeding time. Further studies are needed to explore the clinical importance of and SNPs in the platelet function.
[Mh] Termos MeSH primário: Plaquetas/fisiologia
Integrina alfa2/genética
Integrina beta3/genética
Polimorfismo de Nucleotídeo Único/genética
[Mh] Termos MeSH secundário: Adolescente
Adulto
Alelos
Grupo com Ancestrais do Continente Asiático/genética
Tempo de Sangramento/métodos
Coagulação Sanguínea/genética
Fibrinogênio/genética
Genótipo
Seres Humanos
Volume Plaquetário Médio/métodos
Meia-Idade
Fases de Leitura Aberta/genética
Agregação Plaquetária/genética
Tempo de Protrombina/métodos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ITGA2B protein, human); 0 (ITGB3 protein, human); 0 (Integrin alpha2); 0 (Integrin beta3); 9001-32-5 (Fibrinogen)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170224
[Lr] Data última revisão:
170224
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161215
[St] Status:MEDLINE


  10 / 2539 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27829061
[Au] Autor:Hensch NR; Karim ZA; Druey KM; Tansey MG; Khasawneh FT
[Ad] Endereço:Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, United States of America.
[Ti] Título:RGS10 Negatively Regulates Platelet Activation and Thrombogenesis.
[So] Source:PLoS One;11(11):e0165984, 2016.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Regulators of G protein signaling (RGS) proteins act as GTPase activating proteins to negatively regulate G protein-coupled receptor (GPCR) signaling. Although several RGS proteins including RGS2, RGS16, RGS10, and RGS18 are expressed in human and mouse platelets, the respective unique function(s) of each have not been fully delineated. RGS10 is a member of the D/R12 subfamily of RGS proteins and is expressed in microglia, macrophages, megakaryocytes, and platelets. We used a genetic approach to examine the role(s) of RGS10 in platelet activation in vitro and hemostasis and thrombosis in vivo. GPCR-induced aggregation, secretion, and integrin activation was much more pronounced in platelets from Rgs10-/- mice relative to wild type (WT). Accordingly, these mice had markedly reduced bleeding times and were more susceptible to vascular injury-associated thrombus formation than control mice. These findings suggest a unique, non-redundant role of RGS10 in modulating the hemostatic and thrombotic functions of platelets in mice. RGS10 thus represents a potential therapeutic target to control platelet activity and/or hypercoagulable states.
[Mh] Termos MeSH primário: Ativação Plaquetária/genética
Proteínas RGS/genética
Transdução de Sinais/genética
Trombose/genética
[Mh] Termos MeSH secundário: Difosfato de Adenosina/farmacologia
Animais
Tempo de Sangramento
Plaquetas/efeitos dos fármacos
Plaquetas/metabolismo
Western Blotting
Citometria de Fluxo
Hemostasia/genética
Camundongos Knockout
Ativação Plaquetária/efeitos dos fármacos
Agregação Plaquetária/genética
Complexo Glicoproteico GPIIb-IIIa de Plaquetas/metabolismo
Proteínas RGS/metabolismo
Receptores Acoplados a Proteínas-G/agonistas
Receptores Acoplados a Proteínas-G/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Platelet Glycoprotein GPIIb-IIIa Complex); 0 (RGS Proteins); 0 (Receptors, G-Protein-Coupled); 0 (Rgs10 protein, mouse); 61D2G4IYVH (Adenosine Diphosphate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170707
[Lr] Data última revisão:
170707
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161110
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0165984



página 1 de 254 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde